The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: A systematic review and meta-analysis

The Lancet Infectious Diseases

Volumn 13, Issue 1, 2013, Pages 43-54

  Shallcross, Laura J ^a   Fragaszy, Ellen ^a,b   Johnson, Anne M ^a   Hayward, Andrew C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PANTON VALENTINE LEUKOCIDIN;

ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL STRAIN; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; INFECTION RISK; META ANALYSIS; MORBIDITY; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL INFECTION; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; SKIN SURGERY; SOFT TISSUE INFECTION; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS INFECTION; SYSTEMATIC REVIEW;

BACTERIAL TOXINS; EXOTOXINS; HUMANS; LEUKOCIDINS; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84871055980     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70238-4     Document Type: Article

References (93)

1. Gorwitz RJ, Kruszon-Moran D, McAllister SK, et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis 2008, 197:1226-1234.
2. Hayward A, Knott F, Petersen I, et al. Increasing hospitalizations and general practice prescriptions for community-onset staphylococcal disease, England. Emerg Infect Dis 2008, 14:720-726.
3. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001, 32:S114-S132.
4. Jevons MP, Coe AW, Parker MT Methicillin resistance in staphylococci. Lancet 1963, 281:904-907.
5. Kaneko J, Kamio Y Bacterial two-component and hetero-heptameric pore-forming cytolytic toxins: structures, pore-forming mechanism, and organization of the genes. Biosci Biotechnol Biochem 2004, 68:981-1003.
6. Vandenesch F, Naimi T, Enright MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003, 9:978-984.
7. Rossney AS, Shore AC, Morgan PM, Fitzgibbon MM, O'Connell B, Coleman DC The emergence and importation of diverse genotypes of methicillin-resistant Staphylococcus aureus (MRSA) harboring the Panton-Valentine leukocidin gene (pvl) reveal that pvl is a poor marker for community-acquired MRSA strains in Ireland. J Clin Microbiol 2007, 45:2554-2563.
8. Otter JA, French GL The emergence of community-associated methicillin-resistant Staphylococcus aureus at a London teaching hospital, 2000-2006. Clin Microbiol Infect 2008, 14:670-676.
9. Zhang K, McClure JA, Elsayed S, Tan J, Conly JM Coexistence of Panton-Valentine leukocidin-positive and -negative community-associated methicillin-resistant Staphylococcus aureus USA400 sibling strains in a large Canadian health-care region. J Infect Dis 2008, 197:195-204.
10. O'Brien FG, Lim TT, Chong FN, et al. Diversity among community isolates of methicillin-resistant Staphylococcus aureus in Australia. J Clin Microbiol 2004, 42:3185-3190.
11. Robinson DA, Kearns AM, Holmes A, et al. Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillin-resistant clone. Lancet 2005, 365:1256-1258.
12. Panton PN, Valentine FCO Staphylococcal toxin. Lancet 1932, 219:506-508.
13. Ward PD, Turner WH Identification of staphylococcal Panton-Valentine leukocidin as a potent dermonecrotic toxin. Infect Immun 1980, 28:393-397.
14. Voyich JM, Otto M, Mathema B, et al. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease?. J Infect Dis 2006, 194:1761-1770.
15. Bubeck WJ, Bae T, Otto M, DeLeo FR, Schneewind O Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 2007, 13:1405-1406.
16. Bubeck WJ, Palazzolo-Ballance AM, Otto M, Schneewind O, DeLeo FR Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis 2008, 198:1166-1170.
17. Montgomery CP, Daum RS Transcription of inflammatory genes in the lung after infection with community-associated methicillin-resistant Staphylococcus aureus: a role for panton-valentine leukocidin?. Infect Immun 2009, 77:2159-2167.
18. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S aureus infections among patients in the emergency department. N Engl J Med 2006, 355:666-674.
19. Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006, 42:647-656.
20. Otter JA, Havill NL, Boyce JM, French GL Comparison of community-associated methicillin-resistant Staphylococcus aureus from teaching hospitals in London and the USA, 2004-2006: where is USA300 in the UK?. Eur J Clin Microbiol Infect Dis 2009, 28:835-839.
21. Holmes A, Ganner M, McGuane S, Pitt TL, Cookson BD, Kearns AM Staphylococcus aureus isolates carrying Panton-Valentine leucocidin genes in England and Wales: frequency, characterization, and association with clinical disease. J Clin Microbiol 2005, 43:2384-2390.
22. Shallcross LJ, Williams K, Hopkins S, Aldridge RW, Johnson AM, Hayward AC Panton-Valentine leukocidin associated staphylococcal disease: a cross-sectional study at a London hospital, England. Clin Microbiol Infect 2010, 16:1644-1648.
23. Vorobieva V, Bazhukova T, Hanssen AM, et al. Clinical isolates of Staphylococcus aureus from the Arkhangelsk region, Russia: antimicrobial susceptibility, molecular epidemiology, and distribution of Panton-Valentine leucocidin genes. APMIS 2008, 116:877-887.
24. Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 2007, 45:315-321.
25. Chini V, Petinaki E, Foka A, Paratiras S, Dimitracopoulos G, Spiliopoulou I Spread of Staphylococcus aureus clinical isolates carrying Panton-Valentine leukocidin genes during a 3-year period in Greece. Clin Microbiol Infect 2006, 12:29-34.
26. Nimmo GR, Coombs GW, Pearson JC, et al. Methicillin-resistant Staphylococcus aureus in the Australian community: an evolving epidemic. Med J Aust 2006, 184:384-388.
27. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999, 29:1128-1132.
28. Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med 2005, 353:1245-1251.
29. Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003, 37:1050-1058.
30. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005, 352:1445-1453.
31. Pannaraj PS, Hulten KG, Gonzalez BE, Mason EO, Kaplan SL Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2006, 43:953-960.
32. Dohin B, Gillet Y, Kohler R, et al. Pediatric bone and joint infections caused by panton-valentine leukocidin-positive Staphylococcus aureus. Pediatr Infect Dis J 2007, 26:1042-1048.
33. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep 1999, 48:707-710. Centers for Disease Control and Prevention.
34. Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005, 352:468-475.
35. Ellis MW, Hospenthal DR, Dooley DP, Gray PJ, Murray CK Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis 2004, 39:971-979.
36. Lee NE, Taylor MM, Bancroft E, et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men. Clin Infect Dis 2005, 40:1529-1534.
37. Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections-Los Angeles County, California, 2002-2003. MMWR Morb Mortal Wkly Rep 2003, 52:88. Centers for Disease Control and Prevention.
38. Guidance on the diagnosis and management of PVL-associated Staphylococcus aureus infections (PVL-SA) in England Health Protection Agency, (accessed July 17, 2012). http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1218699411960.
39. Information for general practitioners. MRSA decolonisation treatment Western Australia Communicable Disease Control Directorate, (accessed July 17, 2012). http://www.public.health.wa.gov.au/cproot/3671/2/GP%20Decolonisation%20Jan%202011.pdf.
40. Robotham JV, Graves N, Cookson BD, et al. Screening, isolation, and decolonisation strategies in the control of meticillin resistant Staphylococcus aureus in intensive care units: cost effectiveness evaluation. BMJ 2011, 343:d5694.
41. Fritz SA, Camins BC, Eisenstein KA, et al. Effectiveness of measures to eradicate Staphylococcus aureus carriage in patients with community-associated skin and soft-tissue infections: a randomized trial. Infect Control Hosp Epidemiol 2011, 32:872-880.
42. Ellis MW, Griffith ME, Dooley DP, et al. Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin-resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled trial. Antimicrob Agents Chemother 2007, 51:3591-3598.
43. Hsu L-Y, Koh T-H, Kurup A, Low J, Chlebicki MP, Tan B-H High incidence of Panton-Valentine leukocidin-producing Staphylococcus aureus in a tertiary care public hospital in Singapore. Clin Infect Dis 2005, 40:486-489.
44. Muttaiyah S, Coombs G, Pandey S, et al. Incidence, risk factors, and outcomes of Panton-Valentine leukocidin-positive methicillin-susceptible Staphylococcus aureus infections in Auckland, New Zealand. J Clin Microbiol 2010, 48:3470-3474.
45. Nickerson EK, Wuthiekanun V, Wongsuvan G, et al. Factors predicting and reducing mortality in patients with invasive Staphylococcus aureus disease in a developing country. PLoS One 2009, 4:6512.
46. Wehrhahn MC, Robinson JO, Pearson JC, et al. Clinical and laboratory features of invasive community-onset methicillin-resistant Staphylococcus aureus infection: a prospective case-control study. Eur J Clin Microbiol Infect Dis 2010, 29:1025-1033.
47. Badiou C, Dumitrescu O, George N, et al. Rapid detection of Staphylococcus aureus Panton Valentine leukocidin in clinical specimens by enzyme-linked immunosorbent assay and immunochromatographic tests. J Clin Microbiol 2010, 48:1384-1390.
48. Johnsson D, Molling P, Stralin K, Soderquist B Detection of Panton-Valentine leukocidin gene in Staphylococcus aureus by LightCycler PCR: clinical and epidemiological aspects. Clin Microbiol Infect 2004, 10:884-889.
49. Breurec S, Fall C, Pouillot R, et al. Epidemiology of methicillin-susceptible Staphylococcus aureus lineages in five major African towns: high prevalence of Panton-Valentine leukocidin genes. Clin Microbiol Infect 2011, 173:633-639.
50. Abdel-Haq N, Al-Tatari H, Chearskul P, et al. Methicillin-resistant Staphylococcus aureus (MRSA) in hospitalized children: correlation of molecular analysis with clinical presentation and antibiotic susceptibility testing (ABST) results. Eur J Clin Microbiol Infect Dis 2009, 28:547-551.
51. Kaltsas A, Guh A, Mediavilla JR, et al. Frequency of panton-valentine leukocidin-producing methicillin-sensitive Staphylococcus strains in patients with complicated skin and soft-tissue infection in Bronx, New York. J Clin Microbiol 2011, 49:2992-2995.
52. Couppie P, Cribier B, Prevost G Leukocidin from Staphylococcus aureus and cutaneous infections: an epidemiologic study. Arch Dermatol 1994, 130:1208-1209.
53. Tong SYC, Lilliebridge RA, Bishop EJ, et al. Clinical correlates of panton-valentine leukocidin (PVL), PVL isoforms, and clonal complex in the Staphylococcus aureus population of Northern Australia. J Infect Dis 2010, 202:760-769.
54. Mesrati I, Saidani M, Ennigrou S, Zouari B, Ben RS Clinical isolates of Pantone-Valentine leucocidin and gamma-haemolysin-producing Staphylococcus aureus: prevalence and association with clinical infections. J Hosp Infect 2010, 75:265-268.
55. Schaumburg F, Ngoa UA, Kosters K, et al. Virulence factors and genotypes of Staphylococcus aureus from infection and carriage in Gabon. Clin Microbiol Infect 2011, 17:1507-1513.
56. Lo WT, Lin WJ, Tseng MH, Wang SR, Chu ML, Wang CC Methicillin-resistant Staphylococcus aureus in children, Taiwan. Emerg Infect Dis 2006, 12:1267-1270.
57. Thomsen I, McKenna BD, Saye EJ, Jimenez N, Edwards KM, Creech CB Molecular distinctions exist between community-associated methicillin-resistant Staphylococcus aureus colonization and disease associated isolates in children. Pediatr Infect Dis J 2011, 30:418-421.
58. Sdougkos G, Chini V, Papanastasiou DA, et al. Community-associated Staphylococcus aureus infections and nasal carriage among children: molecular microbial data and clinical characteristics. Clin Microbiol Infect 2008, 14:995-1001.
59. Masiuk H, Kopron K, Grumann D, et al. Association of recurrent furunculosis with Panton-Valentine leukocidin and the genetic background of Staphylococcus aureus. J Clin Microbiol 2010, 48:1527-1535.
60. Carrillo-Marquez MA, Hulten KG, Hammerman W, Lamberth L, Mason EO, Kaplan SL Staphylococcus aureus pneumonia in children in the era of community-acquired methicillin-resistance at Texas Children's Hospital. Pediatr Infect Dis J 2011, 30:545-550.
61. Geng W, Yang Y, Wu D, et al. Community-acquired, methicillin-resistant Staphylococcus aureus isolated from children with community-onset pneumonia in China. Pediatr Pulmonol 2010, 45:387-394.
62. Peyrani P, Allen M, Wiemken TL, et al. Severity of disease and clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus strains not influenced by the presence of the panton-valentine leukocidin gene. Clin Infect Dis 2011, 53:766-771.
63. Dailiana ZH, Rigopoulos N, Varitimidis SE, Poultsides L, Petinaki E, Malizos KN Clinical and epidemiological features of upper-extremity infections caused by Staphylococcus aureus carrying the PVL gene: a four-year study in Greece. Med Sci Monit 2008, 14:CR511-CR514.
64. Martinez-Aguilar G, Avalos-Mishaan A, Hulten K, Hammerman W, Mason J, Kaplan SL Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J 2004, 23:701-706.
65. Gubbay JB, Gosbell IB, Barbagiannakos T, Vickery AM, Mercer JL, Watson M Clinical features, epidemiology, antimicrobial resistance, and exotoxin genes (including that of Panton-Valentine leukocidin) of gentamicin-susceptible methicillin-resistant Staphylococcus aureus (GS-MRSA) isolated at a paediatric teaching hospital in New South Wales, Australia. Pathology 2008, 40:64-71.
66. Jahamy H, Ganga R, Al Raiy B, et al. Staphylococcus aureus skin/soft-tissue infections: the impact of SCCmec type and Panton-Valentine leukocidin. Scand J Infect Dis 2008, 40:601-606.
67. Kanerva M, Salmenlinna S, Vuopio-Varkila J, et al. Community-associated methicillin-resistant Staphylococcus aureus isolated in Finland in 2004 to 2006. J Clin Microbiol 2009, 47:2655-2657.
68. Munckhof WJ, Nimmo GR, Carney J, et al. Methicillin-susceptible, non-multiresistant methicillin-resistant and multiresistant methicillin-resistant Staphylococcus aureus infections: a clinical, epidemiological and microbiological comparative study. Eur J Clin Microbiol Infect Dis 2008, 27:355-364.
69. Nimmo GR, Schooneveldt JM, Sutherland JL, et al. Epidemiology of non-multiresistant methicillin-resistant Staphylococcus aureus infection in Queensland, Australia: associations with indigenous populations and Panton-Valentine leukocidin. Eur J Clin Microbiol Infect Dis 2010, 29:1253-1259.
70. Sharma-Kuinkel BK, Ahn SH, Rude TH, et al. Presence of genes encoding the Panton Valentine leukocidin (PVL) is not the primary determinant of outcome in patients with hospital acquired pneumonia due to Staphylococcus aureus. J Clin Microbiol 2012, 50:848-856.
71. Hamilton SM, Bryant AE, Carroll KC, et al. In vitro production of panton-valentine leukocidin among strains of methicillin-resistant Staphylococcus aureus causing diverse infections. Clin Infect Dis 2007, 45:1550-1558.
72. Diep BA, Palazzolo-Ballance AM, Tattevin P, et al. Contribution of Panton-Valentine leukocidin in community-associated methicillin-resistant Staphylococcus aureus pathogenesis. PLoS One 2008, 3:e3198.
73. Otter JA, French GL Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe. Lancet Infect Dis 2010, 10:227-239.
74. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF Community-associated meticillin-resistant Staphylococcus aureus. Lancet 2010, 375:1557-1568.
75. Mertz D, Frei R, Jaussi B, et al. Throat swabs are necessary to reliably detect carriers of Staphylococcus aureus. Clin Infect Dis 2007, 45:475-477.
76. Ide L, Lootens J, Thibo P The nose is not the only relevant MRSA screening site. Clin Microbiol Infect 2009, 15:1192-1193.
77. Miller LG, Eells SJ, Taylor AR, et al. Staphylococcus aureus colonization among household contacts of patients with skin infections: risk factors, strain discordance, and complex ecology. Clin Infect Dis 2012, 54:1523-1535.
78. Fan J, Shu M, Zhang G, et al. Biogeography and virulence of Staphylococcus aureus. PLoS One 2009, 4:e6216.
79. Morrison MA, Hageman JC, Klevens RM Case definition for community-associated methicillin-resistant Staphylococcus aureus. J Hosp Infect 2006, 62:241.
80. Millar BC, Loughrey A, Elborn JS, Moore JE Proposed definitions of community-associated meticillin-resistant Staphylococcus aureus (CA-MRSA). J Hosp Infect 2007, 67:109-113.
81. Otter JA, French GL Utility of antimicrobial susceptibility-based algorithms for the presumptive identification of genotypically-defined community-associated methicillin-resistant Staphylococcus aureus at a London teaching hospital. Eur J Clin Microbiol Infect Dis 2011, 30:459-463.
82. Popovich K, Hota B, Rice T, Aroutcheva A, Weinstein RA Phenotypic prediction rule for community-associated methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2007, 45:2293-2295.
83. Benoit SR, Estivariz C, Mogdasy C, et al. Community strains of methicillin-resistant Staphylococcus aureus as potential cause of healthcare-associated infections, Uruguay, 2002-2004. Emerg Infect Dis 2008, 14:1216-1223.
84. Otter JA, French GL Community-associated meticillin-resistant Staphylococcus aureus strains as a cause of healthcare-associated infection. J Hosp Infect 2011, 79:189-193.
85. Davis SL, Rybak MJ, Amjad M, Kaatz GW, McKinnon PS Characteristics of patients with healthcare-associated infection due to SCCmec type IV methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 2006, 27:1025-1031.
86. Moore CL, Hingwe A, Donabedian SM, et al. Comparative evaluation of epidemiology and outcomes of methicillin-resistant Staphylococcus aureus (MRSA) USA300 infections causing community- and healthcare-associated infections. Int J Antimicrob Agents 2009, 34:148-155.
87. Tacconelli E, Carmeli Y, Aizer A, Ferreira G, Foreman MG, D'Agata EMC Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin Infect Dis 2003, 37:1629-1638.
88. Fraser TG, Fatica C, Scarpelli M, et al. Decrease in Staphylococcus aureus colonization and hospital-acquired infection in a medical intensive care unit after institution of an active surveillance and decolonization program. Infect Control Hosp Epidemiol 2010, 31:779-783.
89. Ridenour G, Lampen R, Federspiel J, Kritchevsky S, Wong E, Climo M Selective use of intranasal mupirocin and chlorhexidine bathing and the incidence of methicillin-resistant Staphylococcus aureus colonization and infection among intensive care unit patients. Infect Control Hosp Epidemiol 2007, 28:1155-1161.
90. Bode LGM, Kluytmans JAJW, Wertheim HFL, et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med 2010, 362:9-17.
91. Shallcross LJ, Mbeledogu CN, Hayward AC Should we screen and decolonise contacts of patients with Panton Valentine leukocidin associated Staphylococcus aureus infection?. BMJ 2011, 343:d5479.
92. Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA Strategies for clinical management of MRSA in the Community: Summary of an experts' meeting convened by the US Centers for Disease Control and Prevention Participants in the CDC-Convened Experts' Meeting on Management of MRSA in the Community, (accessed July 07, 2012). http://www.cdc.gov/mrsa/pdf/MRSA-Strategies-ExpMtgSummary-2006.pdf.
93. Barton M, Hawkes M, Moore D, et al. Guidelines for the prevention and management of community-associated methicillin-resistant Staphylococcus aureus: a perspective for Canadian health care practitioners. Can J Infect Dis Med Microbiol 2006, 17:4C-24C.